Saturday 17 October 2026
Export PCVX’s income statement to Excel — free account
Vaxcyte, Inc.
PCVX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 61.5% and free cash flow fell 92.6%, each against the same quarter a year earlier.
63.62
1.65
−2.53%
Follow PCVX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (36.51%) | (30.55%) | (25.59%) | (20.83%) |
+8 more TTM periods Free account |
|
| (33.03%) | (28.14%) | (23.54%) | (19.53%) | ||
ROIC |
(57.30%) | (54.05%) | (51.34%) | (42.93%) | |
Return on Tangible Assets |
(69.03%) | (51.66%) | (45.66%) | (36.10%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(6.19) | (5.59) | (4.92) | (4.09) | |
Free Cash Flow |
(894.14) | (780.32) | (669.29) | (557.23) | |
Capital Expenditures |
(12.90) | (10.40) | (13.71) | (15.08) | |
| Other line items | |||||
Cash ROIC |
(21.06%) | (16.49%) | (15.76%) | (12.10%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.83 | 0.81 | 0.86 | 0.82 | |
Depreciation/Fixed assets |
0.07 | 0.05 | 0.04 | (0.01) | |
Capex/Depreciation |
(0.74) | (0.79) | (1.32) | 4.31 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(6.10) | (5.52) | (4.82) | (3.98) | |
Capex per Share |
(0.09) | (0.07) | (0.10) | (0.11) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates